Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
RESEARCH TOOLSreports
Holding NTLA?
Track your performance easily
NTLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.25 - $34.87
Previous CloseN/A
Volume723.92K
Average Volume (3M)2.85M
Market Cap
$1.12B
Enterprise Value$1.52B
Total Cash (Recent Filing)$273.06M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.10
Next Earnings
Feb 20, 2025EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.45
Shares Outstanding101,848,570
10 Day Avg. Volume3,773,964
30 Day Avg. Volume2,853,242
Standard Deviation0.24
R-Squared0.16
Alpha-0.00089
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)25.98
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue35.26
Enterprise Value/Gross Profit41.88
Enterprise Value/Ebitda-3.08
Forecast
1Y Price Target
$42.61Price Target Upside321.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Intellia Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressSwift enrollment in Phase 3 for ATTR-CM is seen as a promising sign of patient acceptance of gene editing.
Financial StabilityThe extended cash runway into the first half of 2027 provides financial stability and supports the potential launch of NTLA-2002 in the US.
Product PotentialSustained ~90% TTR knockdown achieved by nex-z in ATTR-PN patients is highly competitive, especially compared to treatments requiring frequent administrations.
Bears Say
Competition And Market PositionGrowing competition in the transthyretin amyloidosis (ATTR) space has exerted pressure on the stock, raising concerns about the company's ability to maintain its market position.
Financial Performance And Investor SentimentThe continued use of the ATM program to raise funds could result in a near-term headwind for shares, reflecting investor concerns about the company's financial stability.
Strategic ReorganizationThe company's decision to discontinue the NTLA-3001 program and reduce its workforce by 27% suggests significant shifts in its strategic priorities, potentially impacting future growth prospects.
---
Ownership Overview
1.69% Insiders
21.04% Mutual Funds
0.42% Other Institutional Investors
46.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $9.25 and its highest was $34.87 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.12B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 21 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.39 by $0.05.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -1.33.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,848,570 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.39. Following the earnings report the stock price went down -0.374%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 252M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.61 (321.05% Upside)
$42.61 (321.05% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $824.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.14%
12-Months-Change
Fundamentals
Return on Equity
-54.26%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
NTLA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented significant progress in Intellia's clinical pipeline and financial management, with notable achievements in CRISPR-based treatments and regulatory clearances. However, challenges such as decreased collaboration revenue and increased operational expenses were also highlighted.Read More>---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$42.61
▲(321.05% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
13/38 ratings generated profit
1 Year Average Return
+85.81%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +85.81% per trade.
---